GSK269962A
|
|
|
- CAS-Nr.
- 850664-21-0
- Englisch Name:
- GSK269962A
- Synonyma:
- CS-1126;GSK 269962;GSK269962B;GSK-269962 95%;GSK269962A(GSK269962);GSK269962 (GSK269962A);GSK269962A/GSK 269962A;ROCK inhibitor GS269962A;ROCK inhibitor GSK269962A;GSK269962A ISO 9001：2015 REACH
- CBNumber:
- CB52546776
- Summenformel:
- C29H30N8O5
- Molgewicht:
- 570.6
- MOL-Datei:
- 850664-21-0.mol
|
GSK269962A Eigenschaften
- Schmelzpunkt:
- 125 - 127°C
- Dichte
- 1.45
- storage temp.
- under inert gas (nitrogen or Argon) at 2–8 °C
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Solid
- pka
- 13.19±0.70(Predicted)
- Farbe
- Off-White
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
GSK269962A Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Two Rho-associated kinases (ROCKS), ROCK1 and ROCK2, act downstream of the G protein Rho to regulate cytoskeletal stability. The ROCKs play important roles in diverse cellular functions including cell adhesion and proliferation, smooth muscle contraction, and stem cell renewal. GSK269962 is a selective ROCK inhibitor with IC
50 values of 1.6 and 6 nM for ROCK1 and ROCK2, respectively. It displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. GSK269962 has been shown to block the generation of inflammatory cytokines in lipopolysaccharide-stimulated monocytes and to induce vasorelaxation in preconstricted rat aorta (IC
50 = 35 nM). Oral administration of 1-30 mg/kg GSK269962 can dose-dependently lower blood pressure in spontaneously hypertensive rats.
Verwenden
GSK 269962 is a potent and selective Rho kinase (ROCK) inhibitor.
GSK269962A Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
GSK269962A Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 89)Lieferanten
- GSK 269962
- N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide
- GSK269962A(GSK269962)
- N-(3-((2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl)oxy)phenyl)-4-(2-morpholinoethoxy)benzamide
- GSK269962A ISO 9001：2015 REACH
- GSK269962 (GSK269962A)
- ROCK inhibitor GSK269962A
- GSK-269962 95%
- GSK269962B
- GSK 269962A;GSK-269962A;GSK269962;GSK 269962;GSK-269962
- ROCK inhibitor GS269962A
- N-[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]benzamide
- CS-1126
- anti-inflammatory,ROCK,pressure,blood,antihypertensive,Rho-associated protein kinase,Inhibitor,GSK-269962,Rho-associated kinase,ROK,ROCK2,inhibit,GSK-269962A,GSK269962,vasodilatory,Rho-kinase,GSK269962A,ROCK1,cardiovascular
- GSK269962A/GSK 269962A
- 850664-21-0
